Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma

Phase 2

Completed

Conditions: Adult Medulloblastoma

Interventions: Other: Pharmacological Study
Drug: Vismodegib

Registration Number: NCT00939484

Lead Sponsor: National Cancer Institute (NCI)

Brief Summary: This phase II trial is studying how well vismodegib works in treating adult patients with recurrent or refractory medulloblastoma. Vismodegib may slow the growth of tumor cells and may be an effective treatment for medulloblastoma.

Detailed Description: PRIMARY OBJECTIVES:

I. To estimate the efficacy of GDC-0449 (vismodegib) treatment for adult patients with recurrent or refractory medulloblastoma, as measured by the objective response rates for patients without (Stratum A) and with (Stratum B) evidence of activation of Sonic Hedgehog (SHH) signaling pathway tumors.

SECONDARY OBJECTIVES:

I. To assess the safety and tolerability of GDC-0449 administered on a once daily schedule.

II. To estimate the duration of objective response and progression-free survival (PFS).

III. To characterize the pharmacokinetics (plasma and cerebrospinal fluid) of GDC-0449 in adults with refractory medulloblastoma.

IV. To document pathologic and genomic methods to identify CNS tumors with activation of the PTCH/SHH pathway.

V. To describe the objective responses observed in patients whose pathologic assessment of tumor result in unknown (Stratum C) evidence of activation of Sonic Hedgehog (SHH) signaling pathway tumors.

OUTLINE: This is a multicenter study. Patients are stratified according to PTCH/Sonic Hedgehog signaling pathway activation (inactivated vs activated vs unknown).

Patients receive vismodegib orally (PO) once daily on days 1-28. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up periodically for up to 12 months.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 31

Inclusion Criteria

Patients with a histologically confirmed diagnosis of medulloblastoma (including posterior fossa PNET) that is recurrent, progressive, or refractory to standard therapy and for which there is no known curative therapy are eligible; there must be evidence of residual measurable disease or lesion in pre-study MRI as described in section; patients with spinal disease that is measurable will be eligible
The diagnosis should be confirmed at the treating institution and tissue (either from the diagnosis or relapse or preferably from both time points) must be available for biological studies
Patients with neurological deficits should have deficits that are stable for a minimum of 1 week prior to registration; this is to be documented in the database
Eastern Cooperative Oncology Group (ECOG) performance status 0- 2
No other myelosuppressive chemotherapy or immunotherapy within 4 weeks prior to study entry (6 weeks if prior nitrosourea)
Decadron dose should also be stable or decreasing for at least 1 week (7days) prior to starting therapy
Radiation therapy (XRT) >= 3 months prior to study entry for craniospinal irradiation (>= 23 Gy); >= 8 weeks for local irradiation to primary tumor; >= 2 weeks prior to study entry for focal irradiation for symptomatic metastatic sites
Off all colony stimulating factors >= 1 week prior to study entry (GCSF, GM CSF, erythropoietin)
Absolute neutrophil count (ANC) >= 1000/μL
Platelet count >= 50,000/uL (transfusion independent)
Hemoglobin >= 8.0 gm/dL (may receive RBC transfusions)
Creatinine clearance or radio-isotope GFR >= 70ml/min/1.73 m2 or
A serum creatinine =< 2.0 mg/dL
Total bilirubin =< 1.5 x upper limit of normal (ULN) for age
Serum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) =< 2.5 x institutional ULN
Serum glutamic-oxalacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 2.5 times institutional ULN
Serum albumin >= 2.5 g/dL
Patient must have recovered from the significant acute toxicities of all prior therapy before entering this study and meet all other eligibility criteria
Pregnancy should be avoided for 12 months after the last dose of GDC-0449 for females of child-bearing potential; female patients of childbearing potential must not be pregnant or breast-feeding; female patients of childbearing potential must have a negative serum or urine pregnancy test within 24 hours prior to beginning treatment
Women of childbearing potential are required to use 2 forms of acceptable contraception, including one barrier method during participation in the study and for the 12 months following the last dose; for medical or personal reasons, 100% commitment to abstinence is considered an acceptable form of birth control. All patients should receive contraceptive counseling either by the investigator, or by an OB/gynecologist or other physician who is qualified in this area of expertise; prior to dispensing GDC-0449, the investigator must confirm and document the patient's use of two contraceptive methods, dates of negative pregnancy test, and confirm the patient's understanding of the of GDC-0449 to cause spontaneous abortion or birth defects
Signed informed consent according to institutional guidelines must be obtained

Exclusion Criteria

Patients with any clinically significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction), that would compromise the patient's ability to tolerate protocol therapy or would likely interfere with the study procedures or results
Patients receiving any other anticancer or investigational drug therapy
Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy
Life expectancy < 12 weeks as determined by treating physician
Inability to swallow capsules
Prior treatment with GDC-0449 or other antagonists of the HH pathway
Malabsorption syndrome or other condition that would interfere with enteral absorption
History of congestive heart failure
History of ventricular arrhythmia requiring medication
Uncontrolled hypocalcemia, hypomagnesemia, hyponatremia or hypokalemia defined as less than the lower limit of normal for the institution despite adequate electrolyte supplementation
Congenital long QT syndrome

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Treatment (vismodegib)	Pharmacological Study	Patients receive vismodegib PO once daily on days 1-28. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
Treatment (vismodegib)	Vismodegib	Patients receive vismodegib PO once daily on days 1-28. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measures

Name	Time	Method
Objective Response (CR+PR) Sustained for ≥ 8 Weeks	Up to 12 months	Objective response is either a complete response or a partial response sustained for 8 weeks in a patient. The objective response rate will be reported separately for patients of each stratum. CR is complete disappearance of all enhancing tumor. PR is \>= 50% reduction in tumor size.

Secondary Outcome Measures

Name	Time	Method
Progression-free Survival	From start of treatment up to 2 years	Progression-free survival (PFS) is measured from the date of initial treatment with GDC-0449 until the earliest of progression or death on study. PFS is censored at the last tumor assessment date for patients without disease progression who have not died within 30 days of last exposure to study treatment. Kaplan-Meier method is used to estimate the progression-free survival.
Duration of Objective Response	From start of treatment up to 2 years	The duration of objective response is measured from the initial scan documenting complete or partial response that was subsequently confirmed until the earlier of documented progression or death on study. Duration of objective response is censored at the last tumor assessment date for patients without disease progression who have not died within 30 days of last exposure to study treatment.
Pharmacokinetic Parameters of Vismodegib, CSF Penetration	up to 12 month	The estimated median of cerebrospinal fluid (CSF) drug penetration is reported when expressed as an AUC ratio of CSF vismodegib to that of unbound drug in plasma.

Trial Locations

Locations (13): Children's Hospital of Philadelphia
🇺🇸
Philadelphia, Pennsylvania, United States
Children's Hospital of Pittsburgh of UPMC
🇺🇸
Pittsburgh, Pennsylvania, United States
UCSF Medical Center-Mount Zion
🇺🇸
San Francisco, California, United States
Lucile Packard Children's Hospital Stanford University
🇺🇸
Palo Alto, California, United States
Duke University Medical Center
🇺🇸
Durham, North Carolina, United States
Cincinnati Children's Hospital Medical Center
🇺🇸
Cincinnati, Ohio, United States
St. Jude Children's Research Hospital
🇺🇸
Memphis, Tennessee, United States
Lurie Children's Hospital-Chicago
🇺🇸
Chicago, Illinois, United States
Children's Hospital Los Angeles
🇺🇸
Los Angeles, California, United States
Children's National Medical Center
🇺🇸
Washington, District of Columbia, United States
Baylor College of Medicine
🇺🇸
Houston, Texas, United States
Memorial Sloan-Kettering Cancer Center
🇺🇸
New York, New York, United States
Pediatric Brain Tumor Consortium
🇺🇸
Memphis, Tennessee, United States